Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis by Keck, Thomas M. et al.
Rowan University 
Rowan Digital Works 
Faculty Scholarship for the College of Science & 
Mathematics College of Science & Mathematics 
3-31-2015 
Identifying Medication Targets for Psychostimulant Addiction: 
Unraveling the Dopamine D3 Receptor Hypothesis 
Thomas M. Keck 
Rowan University, keckt@rowan.edu 
William S. John 
Paul W. Czoty 
Michael A. Nader 
Amy Hauck Newman 
Follow this and additional works at: https://rdw.rowan.edu/csm_facpub 
 Part of the Medicinal-Pharmaceutical Chemistry Commons 
Let us know how access to this document benefits you - 
share your thoughts on our feedback form. 
Recommended Citation 
Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; and Newman, Amy Hauck, 
"Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor 
Hypothesis" (2015). Faculty Scholarship for the College of Science & Mathematics. 31. 
https://rdw.rowan.edu/csm_facpub/31 
This Article is brought to you for free and open access by the College of Science & Mathematics at Rowan Digital 
Works. It has been accepted for inclusion in Faculty Scholarship for the College of Science & Mathematics by an 
authorized administrator of Rowan Digital Works. For more information, please contact rdw@rowan.edu. 
Identifying Medication Targets for Psychostimulant Addiction:
Unraveling the Dopamine D3 Receptor Hypothesis
Thomas M. Keck,†,‡ William S. John,§ Paul W. Czoty,§ Michael A. Nader,§ and Amy Hauck Newman*,†
†Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug AbuseIntramural
Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States
‡Department of Chemistry & Biochemistry, College of Science and Mathematics; Department of Biomedical & Translational
Sciences, School of Biomedical Science & Health Professions, Rowan University, 201 Mullica Hill Road, Glassboro, New Jersey
08028, United States
§Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157-1083,
United States
*S Supporting Information
ABSTRACT: The dopamine D3 receptor (D3R) is a target
for developing medications to treat substance use disorders.
D3R-selective compounds with high aﬃnity and varying
eﬃcacies have been discovered, providing critical research
tools for cell-based studies that have been translated to in vivo
models of drug abuse. D3R antagonists and partial agonists
have shown especially promising results in rodent models of
relapse-like behavior, including stress-, drug-, and cue-induced
reinstatement of drug seeking. However, to date, translation to
human studies has been limited. Herein, we present an
overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compounds toward clinical utility,
especially for treatment of cocaine abuse. Future research and development of D3R-selective antagonists and partial agonists for
substance abuse remains critically important but will also require further evaluation and development of translational animal
models to determine the best time in the addiction cycle to target D3Rs for optimal therapeutic eﬃcacy.
1. INTRODUCTION
A decade ago, we (A.H.N. and M.A.N.) wrote a Perspective
entitled Dopamine D3 Receptor Partial Agonists and Antagonists
as Potential Drug Abuse Therapeutics.1 We posited that, as all
drugs of abuse either directly or indirectly increase dopamine
(DA) levels in the mesolimbic region of the brain, DA
receptors were one obvious target for medication development.
We highlighted the supporting literature up to that time,
focusing on the DA D3 receptor (D3R), and further
emphasized that despite tremendous progress in identifying
mechanistic underpinnings of the psychoactive actions of
addictive drugs, particularly for the psychostimulants such as
cocaine and methamphetamine (METH), not a single
pharmacological treatment had been approved by the FDA.
As millions of people in the United States and worldwide suﬀer
from psychostimulant abuse and addiction, the public health
need to develop medications to treat these substance use
disorders was and remains signiﬁcant. Since 2005, more than
6000 papers have been published on basic, preclinical, and
clinical cocaine abuse research in an eﬀort to develop eﬀective
treatments. Nonetheless, despite our best eﬀorts with
hypothesis-driven investigations producing promising results
in animal models of psychostimulant addiction, we have not yet
succeeded in identifying a single medication that can meet FDA
safety and eﬃcacy requirements in this population of patients.
The broader question is why have we failed? A narrower
question, and the focus of this Perspective, relates directly to
the development of medications that target the D3R. In this
review, we once again set the stage for the D3R as a lead target
for medication discovery for psychostimulant addiction and
highlight the application of small molecule structure−activity
relationships (SAR), with the aid of structure-based design
using the D3R crystal structure,2−4 toward novel drug-like
molecules. We then illustrate some of the challenges of moving
our basic hypotheses through the rigors of drug development
using our lead molecule 1 (PG648, Chart 1)5 as an example.
All known addictive drugs enhance DA signaling within key
corticolimbic circuits of the brain that control reward, emotion,
cognition, and motivation. Although the molecular targets of
addictive drugs vary widely,6 they all appear to directly or
indirectly enhance DA signaling in the ventral striatum,
particularly the nucleus accumbens,7,8 and activate neural
circuitry that normally mediates reward responses to natural
stimuli such as food and sex. Other dopaminergic pathways that
project into the dorsal striatum and frontal cortex have also
been identiﬁed as contributing to drug reward and may be
especially aﬀected in the progression to addiction.7,9 Speciﬁ-
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cally, psychostimulant drugs directly increase synaptic DA by
altering the function of the DA transporter (DAT). DAT
blockers (e.g., cocaine, methylphenidate) inhibit DA removal
from the synaptic cleft; DAT substrates (e.g., amphetamines)
have more complex actions and can induce nonvesicular DA
release into the synapse.10 The commonality between these
mechanistically distinct drugs of abuse is that rapid and
profound increases in synaptic DA lead to stimulation of DA
receptors, producing the stimulant and rewarding euphoric
eﬀects that can lead to abuse and addiction. What makes
cocaine unique, though, is the rapid reversal of elevated DA,
leading to compulsive drug taking.11,12 For example, cocaine
and methylphenidate have similar regional distributions in the
striatum, but the rapid pharmacokinetics of cocaine likely lead
to its higher abuse potential.12
DA signaling is mediated by a family of G protein-coupled
receptors (GPCRs). The ﬁve known DA receptors (D1R−
D5R) are classiﬁed into two families on the basis of sequence
similarity and second messenger activity. D1-like receptors
(D1R and D5R) signal through Gαs and enhance the
production of intracellular cyclic AMP (cAMP); D2-like
receptors (D2R, D3R, and D4R) signal through Gαi/o and
inhibit the production of intracellular cAMP.
In comparison to D2R pharmacology, D3R pharmacology
has been historically more enigmatic. D3Rs have relatively small
shifts in agonist binding aﬃnity in response to guanyl
nucleotides, which may indicate relatively poor receptor
coupling to G proteins or, alternatively, that the receptor
structure is relatively rigid and only modestly aﬀected by G
protein association; relatedly, D3R receptor high- and low-
aﬃnity states are reported to diﬀer only 5−10-fold in
heterologous systems.13 D3Rs do couple to G proteins in
heterologous systems, but not exclusively to Gαi/o (some
signaling through Gαq has been reported), and the adenylate
cyclase V isozyme is required for agonist-mediated inhibition of
cAMP production.13,14 Furthermore, recent evidence indicates
that D3Rs likely form functional heteromers with D1Rs in the
striatum.15,16 The functional consequences of this interaction in
vivo have yet to be elucidated, but it may play an important role
in a variety of neuropsychiatric disorders.17
The D3R has long been a target of interest in addiction
pharmacotherapy due to its relatively focal localization within
the ventral striatum and its enhanced expression in drug-
exposed brains.1,18,19 Several research groups have discovered
highly selective D3R antagonists, partial agonists, and full
agonists using small molecule SAR (for recent reviews, see refs
20−22) and more recently using the D3R crystal structure,
computational methods, and molecular pharmacology.2,3,18,23,24
Many of these D3R-selective ligands have served as essential
research tools for pharmacological investigations at the
molecular, cellular, and behavioral levels.
Herein, we brieﬂy discuss the history of D3R as a target for
addiction treatment, including a preview of limited clinical
studies. We discuss the viability of identifying a novel
translational candidate for psychostimulant addiction, practical
concerns for future development of D3R-targeted pharmaco-
therapies, and general obstacles to medication development for
addiction. Translation of hypotheses based on preclinical
ﬁndings has proven to be challenging due to the lack of
clinically available, D3R-preferential compounds. One concern
is that failure in the clinic of a single lead molecule could
prematurely eliminate the D3R as a medication target for
addiction pharmacotherapy.
Chart 1. Chemical Structures of Highlighted D3R-Selective Partial Agonists and Antagonists
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Over the past decade, we have discovered many D3R-
selective ligands with varying eﬃcacies as research tools that
have high aﬃnity (Ki < 10 nM) and D3R selectivity (>100-fold
over D2R).5,25,26 One of our lead compounds, N-(4-(4-(2,3-
dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-
carboxamide (1), is a high-aﬃnity D3R-selective antagonist ﬁrst
reported in 2009.5 Computational studies following the
publication of the D3R crystal structure identiﬁed key
interactions within the orthosteric (DA) binding site and the
2,3-diCl-phenylpiperazine moiety of 1, as well as a secondary
binding pocket that together likely contribute to the 4-
phenylpiperazine class of compounds’ aﬃnity, subtype
selectivity, and eﬃcacy.2,27 Further studies determined that
D2R−D3R subtype selectivity of 1 and related compounds
depended critically on a divergent glycine residue in
extracellular loop 1.23 Given the success of earlier and
structurally related compounds 2 (NGB2904),28,29 3
(PG01037),30 and 4 (SB277011A)31 in animal models of
addiction, compound 1’s favorable receptor selectivity proﬁle
made it an enticing preclinical candidate. Hence, we highlight
the development and preclinical evaluation of 1 as an
instructive example of a D3R-selective antagonist that
ultimately will not make it to the clinic; identifying pitfalls in
the medications development process and areas of need in
behavioral models of addiction.
2. RATIONALE: D3R AS A PHARMACOTHERAPEUTIC
TARGET FOR PSYCHOSTIMULANT ADDICTION
As a substantial cause of morbidity and mortality, drug
addiction exerts major sociological and ﬁnancial costs on
individuals and society at large. A recent estimate of $500
billion in economic costs to the U.S. alone has been used to
inspire further support and development of Addiction Medicine
Programs.32 However, while there are presently pharmacother-
apeutic options to treat dependence on nicotine,33 alcohol,34
and opiates,35,36 there are currently no FDA-approved
medications for psychostimulant addiction. This deﬁcit in our
medical armamentarium signiﬁcantly reduces what clinicians
can do for psychostimulant abusers, which underscores the
public health need to develop medications for treatment.
It is well-established that prolonged exposure to psychosti-
mulant drugs leads to adaptive neurobiological changes.37 Key
observations that encouraged the development of D3R-speciﬁc
compounds for psychostimulant addiction treatment came
from human postmortem studies showing elevated expression
of D3Rs following acute or chronic exposure to cocaine.38−40
The phenomenon of increased D3R expression has been
conﬁrmed and extended to other drugs, including METH and
alcohol, via animal and human studies using various molecular
biology techniques and PET imaging.41−46 As the focus of this
Perspective is targeting D3R for psychostimulant addiction
treatment, we encourage interested readers to consult other
excellent reviews for discussions of the pharmacotherapeutic
potential of D3R-selective compounds for substance use
disorders associated with other classes of addictive drugs,
including ethanol and opiates.41,47−50
Since the cloning of the D3R gene in 1990,51 several key
diﬀerences have been identiﬁed between D3R and the closely
related D2R (sharing 78% sequence identity in the trans-
membrane and binding domains). D2R expression in the
human brain is widespread but most prominent in the dorsal
striatum;52 D3R expression is overall lower than D2R, and the
distribution of striatal D3R is more limited to ventral regions,
particularly the nucleus accumbens.48,52,53 A recent auto-
radiography study in postmortem human brain tissue reported
that D3R expression is greater and more widespread than has
previously been appreciated, including moderate dorsal striatal
expression (although still lower density than D2R) and
appreciable expression in extrastriatal regions such as the
thalamus.54 The recent development of newer radioligands,
such as 5 ([3H]LS-3-134 in Chart 1), with greater D3R
selectivity over D2R may further resolve the longstanding
diﬃculty in diﬀerentiating D2R and D3R receptor densities in
neuronal tissues.55
The localization of D3Rs within the ventral striatum suggests
the receptor may play an important role in the rewarding eﬀects
of drugs and control of motivational behaviors. The relatively
low D3R density in the dorsal striatum, compared to D2R,
suggests that ligands suﬃciently selective for D3R over D2R
may also avoid the undesirable motor coordination and
extrapyramidal side eﬀects associated with nonselective D2-
like antagonists (e.g., antipsychotics), commonly attributed to
D2R blockade.56,57 Moreover, a recent meta-analysis of
randomized placebo-controlled trials with a variety of neuro-
leptics showed that these clinically available D2R/D3R
antagonists were no more eﬃcacious than placebo in improving
abstinence or reducing craving for cocaine or METH, further
suggesting that nonselective D2-like antagonists do not have
clinical utility in this patient population.58 However, cariprazine
(6, RGH-188, Chart 1), a partial agonist approximately 10-fold
D3R-preferential, is in clinical development as an antipsychotic
agent (for review, see ref 59) and has shown potential utility in
preclinical models of cocaine abuse.60
While the major goal of addiction pharmacotherapy
development is to block drug seeking, there has been recent
interest in also focusing on cognitive deﬁcits induced by long-
term drug abuse.61 In one of the earlier studies, Laszy et al.62
used a water labyrinth test to assess spatial memory in rats and
found that cognitive impairments induced by scopolamine were
reversed by D3R antagonists. More recently, Mugnaini et al.63
reported that the D3R antagonist 7 (GSK598,809 in Chart 1)
partially attenuated an attentional bias, as assessed with a
Stroop Task, in abstinent smokers. In a review on D3R and
cognition, Nakajima et al.64 concluded that D3R blockade
enhances cognitive function, whereas agonists at D3R appear to
impair cognition. Recent preclinical studies suggest that the
mechanism by which D3R blockade improves cognition
involves the facilitation of both cholinergic and DA trans-
mission in the frontal cortex.62,65−67 D3R may also inﬂuence
cognition by modulating CREB signaling in the hippocampus68
as well as through glutamatergic−D3R interactions.69 The
relationship between D3R and cognition is an area of research
that requires much additional work. While Nakajima et al.64
reported reversal in “compromised” animals, it remains to be
determined whether selective D3R antagonists and/or partial
agonists can improve cognition in subjects with cocaine- or
METH-induced cognitive disruptions.
2.1. Designing D3R-Selective Antagonists and Partial
Agonists. The initial success of the partial agonist 8 (BP897 in
Chart 1) in a rodent model of cocaine addiction70 spurred
many laboratories in both academia and pharma to develop
new drug-like molecules with D3R selectivity. SAR studies
published by a number of research groups have been reviewed
previously.1,3,21,71−74 Recently reported analogues in the 4-
phenylpiperazine template include functionalization of the butyl
linking chain5,25,26,75−77 and elaboration of both the terminal
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aryl amide and phenylpiperazine or head group.24 Recently
reported D3R-selective compounds can be seen in Chart 2.
These compounds typically follow and expand upon the SAR
already established for D3R-selective antagonists or partial
agonists and, for those that have been tested in vivo, have
similar behavioral proﬁles in animal models of psychostimulant
abuse. A novel approach that inserted a cyclobutyl group in the
linking chain and replaced the phenylpiperazine head group
with tranylcypromine resulted in a recently reported novel
series of D3R-selective antagonists.78
Many of the newer analogues have capitalized on variations
of the 4-phenylpiperazine template, but some interesting and
diverse molecules have also been discovered. Notably, the
evolution of SAR in the Glaxo program, led by Micheli and
colleagues, abandoned the arylamide terminus for a hetero-
aryltriazole, as seen in 7.20,79 This modiﬁcation resulted in high
aﬃnity and selectivity for the D3R target but also metabolic
stability and low hERG channel activity, predicting that this
compound would be bioavailable and safe in humans. Other
groups have replaced the 4-phenylpiperazine with the
tetrahydrobenzothiazole of pramipexole to give full80 or
partial81 D3R agonists with both high aﬃnity and subtype
selectivity. Of note, the groups led by Dutta and Reith have also
reported tetrahydrobenzothiazole analogues, but they have
replaced the arylamide of the more classic D3R ligands with
this functional group and retained an arylpiperazine or an
arylamide piperazine to give a novel set of D3R-selective
agonists.82 In this series, it is interesting to contemplate which
end of these molecules binds to the orthosteric (DA) binding
site and whether the other end binds to the secondary binding
pocket believed to be occupied by the aryl amide of (R)-12 or a
diﬀerent site within the D3R protein to produce a full agonist
proﬁle. A similar hybridization approach that replaced the 4-
phenylpiperazine with a 5-aminohydropyrazolopyridine group
also resulted in a very interesting series of highly potent D3R
agonists that were reported to demonstrate functional bias,83 a
hot topic in the D2-like receptor drug discovery arena (for
review, see refs 84 and 85) but beyond the scope of the present
review. Gmeiner and colleagues are avidly following these leads
and discovering other templates that display functionally biased
proﬁles.86,87 The ﬁeld is still in its infancy in terms of
understanding the pharmacological and behavioral consequen-
ces of D3R-mediated biased agonism. Nevertheless, the
combination of small molecule SAR and the D3R crystal
structure with computational modeling will undoubtedly
produce structurally and pharmacologically variant tools in
the near future with which to probe these questions.3
Chart 2. Recently Reported D3R-Preferential Ligands with Novel Structural Templates
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2.2. Translating D3R-Selective Antagonists and Partial
Agonists to the Clinic. To date, very few D3R-selective or
preferential antagonists or partial agonists have been tested in
clinical trials for substance use disorders. Thus far, 7 appears to
be the most clinically investigated compound based on
publications in the literature and perusal of clinicaltrials.gov
(e.g. , ClinicalTrials .gov identiﬁers NCT00437632,
NCT01188967, NCT00793468, NCT00605241, and
NCT01039454).
Brieﬂy, after validating D3R occupancy in a PET study using
[11C]PHNO53 and evaluating its pharmacokinetics,88 7 was
tested in several clinical studies. In overweight and obese
subjects, 7 reduced approach bias89 and attentional bias to
palatable food cues90 but did not alter fMRI brain responses to
food images.91 In tobacco smokers, 7 transiently alleviated
craving in smokers after overnight abstinence, although
smoking increased.63 Although 7 had some qualiﬁed successes
in these clinical populations, and many other D3R-selective
antagonists and partial agonists have been successful in
preclinical models of cocaine or METH abuse, it is unclear at
this time whether or not 7 will be evaluated in this patient
population.
One concern that has emerged is the potential for 7 and
other D3R antagonists to increase blood pressure, especially if
taken in combination with stimulants (Nate Appel and Jane
Acri, National Institute on Drug Abuse, personal communica-
tion), as D3Rs reside in the kidney and contribute to DA-
mediated regulation of blood pressure.92−95 Cocaine’s
cardiovascular eﬀects have been investigated, and increases in
both blood pressure and heart rate have been well-
documented.96,97 Indeed, cardiovascular toxicity is likely the
main contributor to medical complications and overdose. Both
central and peripheral mediation of increased blood pressure
upon acute and chronic administration of cocaine have been
investigated with varying results depending on species, dose of
cocaine, and acute versus chronic administration.96 The
concern, of course, is that if subjects relapse to cocaine taking,
blood pressure elevations due to cocaine exposure could be
exacerbated in the presence of a D3R antagonist. Human
studies investigating the eﬀects of the D2R/D3R partial agonist
aripiprazole on cocaine self-administration, drug discrimination,
and cardiovascular eﬀects reported a small, acute increase in
blood pressure that was not sustained after repeated cocaine
administration.98,99 Further investigation with D3R-selective
drugs is required in order to clearly determine whether D3R-
selective partial agonists or antagonists are likely to exhibit this
potential side eﬀect. For example, in ongoing preclinical studies
using nonhuman primates implanted with indwelling telemetry
devices, administration of cocaine increases blood pressure and
heart rate; these eﬀects are either unaltered or enhanced by
D3R antagonists, but they appear to be attenuated by D3R
partial agonists (M.A. Nader, A.H. Newman, unpublished
results). Also, it is critically important to determine whether
this potential cardiovascular risk is mediated via D3R or is an
oﬀ-target eﬀect of the drug molecule: the latter might be
addressed with appropriate structural modiﬁcations of the lead
compound(s). Hence, continued evaluation of structurally
diverse molecules with diﬀering oﬀ-target proﬁles remains a
priority to further validate the D3R as a target for medication
development, especially for psychostimulant abuse. Of course,
substance use disorders that by themselves do not alter blood
pressure or heart rate may be completely treatable with D3R
antagonists or partial agonists, without concern for cardiovas-
cular safety. In addition, increases in blood pressure can be
monitored and treated, if necessary, with clinically available
drugs.
2.3. Repurposing Buspirone for Treatment of Cocaine
Abuse. In response to the interest in investigating D3R
antagonists as potential pharmacotherapies for cocaine abuse,
the clinically available anxiolytic buspirone was evaluated in
several preclinical addiction models and in a clinical trial with
cocaine abusers. While by no means D3R-selective, Bergman et
al.100 reported that buspirone had higher aﬃnity at the D3R
compared to the D2R. When tested in monkeys self-
administering cocaine, they found that buspirone decreased
cocaine-maintained behavior to a larger degree than food-
reinforced behavior. Mello et al.,101 using rhesus monkeys that
self-administered cocaine 4 times per day, found that
continuous infusions of buspirone also decreased cocaine self-
administration to a greater degree than food-reinforced
responding. These ﬁndings supported the use of buspirone as
a pharmacotherapy for cocaine addiction. Unfortunately, the
positive results from these preclinical studies did not extend to
clinical trials. Winhusen et al.102 reported negative eﬀects of
buspirone in cocaine abusers and, in fact, found that buspirone
increased cocaine use in women. However, it should be noted
that this study had a remarkable placebo eﬀect: subjects that
were not administered buspirone dramatically reduced their
cocaine use. Further, it is not clear that the single tested dose
(60 mg) of buspirone was adequate to achieve high occupancy
of D3R for a suﬃcient duration of time to be eﬀective.102
Supporting this assumption is a recent study in primates
measuring D3/D2R occupancy of buspirone using PET
imaging.103 It was found that the low dose of oral buspirone
(1.0 mg/kg) tested, approximately the same dose tested in the
Winhusen et al. study, exhibited minimal D3R occupancy
(<20%). In contrast, 80% sustained D3R occupancy was
achieved by a dose that was 3-fold higher (3.0 mg/kg) and was
well-tolerated. These data indicate the importance of using
receptor occupancy as a guideline for therapeutic eﬃcacy in
that high and sustained levels are most likely needed for the
successful treatment of addiction.
On the basis of these clinical ﬁndings with buspirone, one
may (prematurely) conclude that the D3R and, more
speciﬁcally, D3R antagonists are not viable targets for
psychostimulant addiction. We would caution against such
conclusions for two reasons: First, buspirone has very complex
pharmacology, with known eﬀects at 5-HT1A, D2R, D3R, and
D4Rs, as well as active metabolites that interact with α2-
adrenergic receptors.100,104,105 Second, the choice of drug
reinforcement schedules used in the preclinical evaluations of
buspirone may not have been ideal to detect D3R-mediated
antiaddiction eﬀects.
One of the interesting aspects of the behavioral pharmacol-
ogy of D3R compounds is the importance of the schedules of
reinforcement used in self-administration studies (see refs 1 and
48 for review). In the preclinical models used by Bergman et
al.100 and Mello et al.,101 there were no competing reinforcers
when cocaine self-administration was studied, and this may be
critical to understanding how medications, such as buspirone,
can decrease one type of behavior (in their case, food-
maintained responding) to a smaller degree than cocaine self-
administration. More complex models, such as food−drug
choice paradigms, measure reinforcing strength (eﬃcacy) with
the goal of examining treatments that decrease cocaine self-
administration and reallocate responding from cocaine to food.
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In a recent study, John et al.106 found that 5 day treatment with
buspirone increased cocaine choice, a ﬁnding consistent with
the Winhusen et al.102 clinical study. Clearly, the animal models
used to evaluate D3R compounds on cocaine self-admin-
istration need to be more thoughtfully analyzed in order to
achieve translation of preclinical ﬁndings to clinical success. For
example, in a study using socially housed monkeys, acute
buspirone administration decreased cocaine choice relative to
food in dominant monkeys but not subordinate animals,
suggesting a possible interaction between environmental
variables and eﬃcacy of buspirone.107 Importantly, though, it
is our premise that using food−drug choice paradigms and the
study of a range of D3R compounds (see below) will allow for
(1) a better understanding of the role of D3Rs in cocaine abuse
and (2) the identiﬁcation of potential pharmacotherapies based
on the D3R. Thus, buspirone should not be considered a
representative D3R antagonist, and it is our perspective that
this single clinical trial should not deter further research toward
developing a D3R-selective antagonist or partial agonist for
substance use disorders. It should, however, be noted that
Chart 3. Behaviorally Tested D3R-Preferential Ligands
Table 1. D2-Like Binding Aﬃnity and Subtype Selectivity of Selected Ligands Using [3H]N-Methylspiperone
D2R D3R D4R subtype selectivity
compound Ki ± SEM (nM)
a Ki ± SEM (nM)
a Ki ± SEM (nM)
a D2/D3 D4/D3 cLogP
N-methylspiperone78 0.133 ± 0.00885 0.265 ± 0.00752 0.461 ± 0.00789 0.50 1.7
eticlopride78 0.0860 ± 0.000951 0.134 ± 0.00437 46.4 ± 6.94 0.64 346
raclopride78 12.7 ± 1.21 13.4 ± 0.695 14 700 ± 357 0.95 1100
butaclamol78 2.58 ± 0.473 6.39 ± 0.584 229 ± 57.0 0.40 36
aripiprazole 0.343 ± 0.0899 1.00 ± 0.0250 57.1 ± 16.2 0.34 57
(±)-1 (PG648)76 746 ± 123 1.88 ± 0.112 2600 ± 660 397 1380 4.8
(R)-176 295 ± 65.0 0.528 ± 0.0910 3980 ± 882 559 7540 4.8
(S)-176 786 ± 160 3.89 ± 0.365 1900 ± 491 202 489 4.8
2 (NGB2904) 54.7 ± 5.20 0.233 ± 0.0089 3670 ± 626 235 15 800 6.7
3 (PG01037) 74.0 ± 16.6 0.316 ± 0.0284 550 ± 28.3 234 1740 5.5
7 (GSK598,809) 2110 ± 485 3.15 ± 0.335 35 600 ± 8,880 670 11 300 2.6
18 (PG619)78 1090 ± 20.6 6.70 ± 0.768 4470 ± 993 163 667 3.3
19 (GCC3-09) 217 ± 35.6 0.920 ± 0.102 2040 ± 677 236 2210 4.9
20 (BAK2-66)76 956 ± 273 10.3 ± 1.98 NT 93 5.3
21 (YQA14) 46.9 ± 7.36 3.04 ± 0.369 2370 ± 223 15 780 3.7
aKi values determined by competitive inhibition of [
3H]N-methylpsiperone binding in membranes harvested from HEK 293 cells stably expressing
hD2R, hD3R, or hD4R. Detailed methods have been described previously76,78 and are in the Supporting Information. NT, not tested. References
indicate previously published binding data using identical methods.
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treatment-emergent adverse events reported in this study did
not include increases in blood pressure in the subjects receiving
buspirone.102
3. RECENT DEVELOPMENT OF NOVEL D3R-SELECTIVE
COMPOUNDS AS IN VIVO TOOLS
On the basis of the preclinical promise of early leads, our group
and others have focused eﬀorts on optimizing D3R aﬃnity and
selectivity as well as physical properties (e.g., cLogP, tPSA,
metabolic stability, etc.) to improve their utility as in vivo tools.
As drug abuse is a human behavior, we ultimately must develop
tools that are stable in vivo, penetrate the blood−brain barrier,
and selectively engage D3R. We must also be able to readily
scale up the synthesis of these molecules for behavioral studies
in rodent and nonhuman primate models, the most transla-
tional of which require chronic dosing. Like other medicinal
chemists, we have optimized lead compounds, using structure−
activity relationships and, more recently, the D3R crystal
structure, to design novel molecules. These eﬀorts have led to
the identiﬁcation of several new lead molecules, including (±)-,
R-, and S-1, 3, and others including 17 (CJB090),108 18
(PG619),75 19 (GCC3-09),5 and 20 (BAK2-66),26 to highlight
a few (Chart 3). These compounds have been evaluated in cell-
based binding assays along with compounds reported in the
literature to obtain side-by-side data comparisons across the
D2-like family of receptors.
3.1. Relative Binding Aﬃnity and D2-Like Receptor
Subtype Selectivity of Dopaminergic Compounds. The
binding aﬃnities of representative D2-like compounds, in Table
1, were obtained from human D2Rs, D3Rs, and D4Rs
expressed in HEK293 cells. Using membranes from these
cells and the antagonist radioligand [3H]N-methylspiperone,
direct comparisons can be made of these structurally divergent
compounds under identical experimental conditions (see
Supporting Information for methods).
Table 1 shows the experimentally derived binding dissoci-
ation constants (Ki) for a number of dopaminergic compounds
with varying selectivities for D3R over D2R and D4R. Of note,
N-methylspiperone, eticlopride, raclopride, and butaclamol are
well-known D2-like antagonists, demonstrating high binding
aﬃnities across the D2-family of receptors, with the notable
exceptions of butaclamol and especially raclopride at D4R.
Aripiprazole is a clinically available D2-like partial agonist,
marketed as Abilify, used in the treatment of schizophrenia and
mood disorders. It binds with high aﬃnity to both D2R and
D3R and has been shown to decrease cocaine self-
administration and attenuate reinstatement in laboratory
animals.109−112 Although mixed results have emerged from
human studies,98,99,113 a recent phase II study using chronic
treatment with lower doses reported that aripiprazole decreased
cocaine craving.114
Because identical binding conditions were used, the data
presented in Table 1 permit direct binding aﬃnity comparisons
across compound classes. Compound 7 was the most subtype-
selective compound in this set, with 670-fold D3R selectivity
over D2R. Notably, binding for 21 (YQA14) in this system did
not show two-site binding kinetics at D3R as reported
previously.115 The Ki determined in this analysis (3.04 nM) is
consistent with the Ki‑Low reported previously (2.11 nM);
coupled with a higher D2R aﬃnity in this analysis than in the
previous report (46.9 vs 335 nM),115 compound 21 appears to
be only moderately preferential for D3R binding over D2R
when compared to others in this class of D3R ligands and
points to the limitations of using cell-based binding aﬃnities to
predict D3R selectivities and potencies in vivo. Nevertheless,
radioligand binding is the ﬁrst line of testing in most drug
discovery programs and is useful as long as compounds are
evaluated side-by side under the same assay conditions. As
noted in our previous Perspective, cell-based functional assay
data remain diﬃcult to interpret from an SAR standpoint;1
hence, binding data remain our primary source of SAR, despite
these limitations.
Compound 2 is one of the ﬁrst D3R-selective antagonists to
be reported116 and has served as an important preclinical tool.
Early reports demonstrated that 2 signiﬁcantly lowered the
break point in rats trained to self-administer cocaine under a
progressive-ratio (PR) schedule of reinforcement.29 PR
schedules require an increase in number of responses following
injections of cocaine and the last ratio completed (the break
point) is thought to be a measure of reinforcing strength.117
Compound 2 also inhibited cocaine-induced enhancement of
brain stimulation reward threshold while neither maintaining
self-administration nor altering brain-reward thresholds on its
own. In addition, 2 blocked both cue- and cocaine-induced
reinstatement of cocaine seeking, a preclinical model of
relapse.28,29,118 Compound 2, along with 4 and 8, was also
evaluated in METH-enhanced brain stimulation reward in rats.
Notably, the two antagonists (2 and 4) eﬀectively attenuated
METH-enhanced brain stimulation reward and did not aﬀect
brain stimulation reward on their own; the partial agonist 8
attenuated METH-enhanced brain stimulation reward, but a
high dose inhibited brain stimulation reward itself.119 Hence, 2,
along with 4 and 8, demonstrated potential for this class of
ligands to be developed toward medications to treat cocaine
and METH abuse. Although none of these agents would be
translated to the clinic, all of them served as templates for the
design of new analogues. While 4 was the precursor to 7,19 2
served as the starting point from which our early lead
compounds 3 and 17 were derived.25,108,120 Compound 17
was the ﬁrst partial agonist in our series that was evaluated in
nonhuman primates and compared to 2 in two models of
cocaine abuse.121 Interestingly, 17, but not 2, attenuated
cocaine’s discriminative stimulus eﬀects and decreased both
cocaine- and food-maintained responding in monkeys that were
trained on a second-order schedule of reinforcement.121
However, in a separate study with squirrel monkeys, 17 failed
to attenuate cocaine self-administration or cocaine-induced
reinstatement of extinguished cocaine-seeking behavior.122 As
elaborated by Achat-Mendes et al.,122 there are several possible
reasons for these discrepant results including the diﬀerent
schedule parameters, the diﬀerent frequencies of cocaine
injection per session (maximally 10 in the Achat-Mendes et
al. study122 and 2 in the Martelle et al. study121), and the
diﬀerent species used (squirrel monkeys vs rhesus monkeys).
Another possible explanation could be the cocaine history of
the subjects, which has been shown to inﬂuence the behavioral
eﬀects of D3R compounds.123−125
Both 17 and the structurally related but more D3R-selective
antagonist 3 reduced PR METH self-administration in rats with
a history of long access (6 h per day, 6 days per week) to
METH.126 17, in contrast to 3, also reduced PR METH self-
administration in rats with a history of short-access to METH
(1 h per day, 3 days per week).126 It is unclear at this time
whether or not diﬀerences in pharmacokinetics or pharmaco-
dynamics can explain these subtle diﬀerences in eﬃcacy across
species and models, although pharmacokinetic and metabolism
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data suggested that 3, like 2, had suboptimal bioavailability.127
Overall, coupled with many other reports in the literature of
similar ﬁndings with compounds such as 4, 7, and newer
generation analogues, these data supported further optimization
and development of D3R-selective antagonists or partial
agonists. Recent reports from the Neisewander lab highlight
novel 4-phenylpiperazines, exempliﬁed by 22 (Chart 3), each
varying in their subtype selectivity and degree of partial
agonism at D3R, that reduce cocaine self-administration.128−130
Compound 17 and a newer-generation partial agonist, 18,75
exhibited interesting eﬀects in rhesus monkeys with a history of
cocaine self-administration in comparison to their drug-naiv̈e
counterparts.123 As part of our eﬀorts to identify D3R-based
behaviors in vivo, a model of D3R-induced yawning in
rats131,132 was modiﬁed, in which yawning could be produced
in rhesus monkeys upon administration of the D3/D2R agonist
quinpirole. In cocaine-naiv̈e animals, quinpirole induces robust
yawning, but the partial agonists 17 and 18 failed to do
so.121,123 However, in monkeys with a history of cocaine self-
administration, both 17 and 18 induced yawning similar in
magnitude to quinpirole.123 We reasoned that increased
sensitivity to yawning might occur in the monkeys with a
cocaine history, as increases in D3R densities had been
reported in both human cocaine fatalities38 as well as in
cocaine-exposed rodents.133 Nevertheless, in that study, 18 was
unable to attenuate cocaine self-administration under a ﬁxed-
ratio (FR) 30 schedule of reinforcement. Unlike quinpirole,
however, 18 did not reinstate cocaine seeking in these monkeys
but rather attenuated cocaine-induced reinstatement.123
In an eﬀort to continue to optimize D3R aﬃnity, selectivity,
and bioavailability, modiﬁcations of these lead molecules have
led to newer generation compounds such as 19 and 1 (Chart
1).5 Both of these compounds have high aﬃnity (Ki 1−2 nM)
for D3R and are highly selective over D2R and other oﬀ-target
receptors.5 Of note, (±)-1 was evaluated in 64 radioligand/
enzyme assays through the NIDA Addiction Treatment
Discovery Program. Other than the reported binding aﬃnities
at D1R (Ki = 4630 nM) and 5-HT1A receptors (Ki = 104 nM),
5
(±)-1 did not produce >50% inhibition of binding at any of the
receptors evaluated at a concentration of 100 nM and only “hit”
a few at 10 μM [e.g., α1 adrenergic, α2 adrenergic, histamine
H1, sodium channel site 2, cholecystokinin 1 (CCK1), and
neurokinin 2 (NK2)]. In addition, the IC50 for (R)-1 at the
hERG channel was 0.38 μM, as determined using the
PatchXpress assay134 through the NIMH Psychoactive Drug
Screening Program (PDSP; http://pdsp.med.unc.edu). Con-
sidering its Ki at D3R is ∼2 nM, (±)-1 was considered to be
highly selective for the D3R, and, despite its marginally
acceptable cLogP value of 4.8, we chose it as our lead candidate
for further development.
The addition of a 3-OH group in the linking chain of these
molecules creates a chiral center; therefore, we synthesized the
R- and S-enantiomers of 1. In radioligand binding competition
studies, we observed a small but signiﬁcant enantioselectivity at
D3R, but not at D2R, with the R-enantiomer having higher
D3R aﬃnity.5 From a structural point of view, this was
signiﬁcant and gave insight on diﬀerential binding interactions
at the receptor protein level that were further explored.5,27 To
determine if behavioral eﬀects were also enantioselective, we
improved the enantioselective synthesis,76 evaluated the
microsomal metabolism and pharmacokinetics of the racemate,
and then tested the racemate and the R- and S-enantiomers in
behavioral models of cocaine and METH abuse.
3.2. Further Development of Lead Compound 1.
3.2.1. Pharmacokinetics and Metabolism Studies of (±)-1 in
Mice. Pharmacokinetic and metabolism studies were performed
in mice. The plasma concentration−time proﬁle of (±)-1 after
i.v. and p.o. dosing of 10 mg/kg is shown in Figure 1. A
summary of the plasma pharmacokinetic parameters is listed in
Table 2. Absorption for oral (±)-1 was slightly delayed, peaking
2 h after administration. The peak plasma concentration (Cmax)
for (±)-1 was 7369 ng/mL following i.v. dosing compared to
522 ng/mL following p.o. dosing; comparing oral versus
intravenous AUC parameters gives a low/moderate average
absolute bioavailability fraction (F%) of 16.2%. The plasma
half-life (t1/2) of i.v. (±)-1 was approximately 75 min. (±)-1
showed excellent brain penetrability following both p.o. and i.v.
dosing, as shown in Table 3. The brain-to-plasma ratio ranged
from 6- to 20-fold for (±)-1.
We investigated the metabolism of (±)-1, and these data are
presented in Table 4. (±)-1 was found to be very stable in
mouse plasma over a period of 60 min, with 90% of the parent
compound remaining. (±)-1 was, however, susceptible to phase
I and phase II hepatic metabolism. In mouse liver microsomal
incubations in the presence of NADPH, which measures phase
I metabolism, 21% of the parent (±)-1 remained after 60 min.
Notably, microsomal stability in rats was increased to 37% of
the parent (±)-1 remaining after 60 min, under the same assay
conditions, suggesting higher stability in this species. In mouse
microsomes fortiﬁed with UDPGA, which measures phase II
metabolism, 55% of the parent (±)-1 remained after 60 min of
incubation. No metabolism was observed in microsomes
without the cofactors, showing their speciﬁcity to CYP- and
UGT-dependent instability, respectively.
3.2.2. Eﬀects of i.p. (±)-, (R)-, and (S)-1 on PR Responding
for METH in Rats. Concurrent with the pharmacokinetic
studies described above, (±)-, (R)-, and (S)-1 were evaluated in
a rat yawning model131 to verify target engagement and
determine an eﬀective dose range for further behavioral
evaluation. Although mouse yawning studies were initially
attempted, it was discovered that D3R agonists do not induce
yawning in mice, so that approach was abandoned. (±)-, (R)-,
and (S)-1 each attenuated 7-OH DPAT-induced yawning in
rats, as demonstrated by a rightward shift in the ascending limb
of the dose−response curve; however, no clear evidence of
enantioselectivity was observed (J.L. Katz and A.H. Newman,
unpublished results). Further, this model proved to be diﬃcult
to use as an in vivo screen for numerous reasons, including
Figure 1. Concentration proﬁles for 10 mg/kg (±)-1 in mouse plasma
following i.v. (○) or p.o. (■) administration. Data are presented as
mean ± SEM; n = 3 mice per time point.
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tolerance to the D3R-agonist eﬀect on yawning and signiﬁcant
variation across subjects. It also required a large quantity of test
drug to obtain full dose−response curves. Hence, we
discontinued testing compounds in the rat yawning model as
an in vivo diagnostic and instead used binding aﬃnities as a
guide to dose ranges evaluated in the subsequent rodent
studies.
Using methods described previously,135,136 1 was evaluated
for its eﬀects in two rat models of drug-taking and drug-seeking
behavior. Figure 2A shows METH self-administration in rats
responding under a PR schedule of reinforcement, comparing
baseline performance against pretreatments with vehicle or the
enantiomers of 1; Figure 2B presents these data normalized to
each individual animal’s baseline performance. Separate one-
way repeated-measures ANOVAs were conducted on number
of injections, which represents PR break points (i.e., the ﬁnal
ratio completed). Compound 1 signiﬁcantly and dose-depend-
ently reduced METH injections [(±)-1: F2,18: 19.36, p <
0.0001, Dunnett’s test: vehicle vs 3.0 mg/kg p > 0.05, vehicle vs
10 mg/kg p < 0.001; (R)-1: F2,18: 11.15, p < 0.001, Dunnett’s
test: vehicle vs 3.0 mg/kg p < 0.01, vehicle vs 10 mg/kg p <
0.01; (S)-1: F2,18: 15.19, p < 0.0001, Dunnett’s test: vehicle vs
3.0 mg/kg p > 0.05, vehicle vs 10 mg/kg p < 0.001]. Similarly,
one-way repeated-measures ANOVA revealed that 1 signiﬁ-
cantly reduced PR break points when normalized to baseline
responding [(±)-1: F2,18: 16.67, p < 0.001, Dunnett’s test:
vehicle vs 3.0 mg/kg p > 0.05, vehicle vs 10 mg/kg p < 0.001;
(R)-1: F2,18: 13.16, p = 0.003, Dunnett’s test: vehicle vs 3.0 mg/
kg p < 0.001, vehicle vs 10 mg/kg p < 0.001; (S)-1: F2,18: 25.16,
p < 0.001, Dunnett’s test: vehicle vs 3.0 mg/kg p < 0.01, vehicle
vs 10 mg/kg p < 0.001]. Although (R)-1 and (S)-1 vary in their
in vitro aﬃnity and selectivity for D3R (Table 1), the doses
studied did not indicate a clear diﬀerential in vivo potency
between enantiomers. Hence, only (±)-1 was tested further.
PR drug self-administration paradigms are often used to
evaluate the reinforcing eﬃcacy of drugs of abuse.137−139
Because the response requirement to receive the next injection
increases continuously, the break point (the last completed
ratio) becomes a repeatable measure of the relative reinforcing
value of a particular commodity (including drug dose). The PR
procedure has been used in a variety of human research eﬀorts,
including some clinical populations, but has not been well-
evaluated in measuring the therapeutic outcomes of pharmaco-
logical interventions in applied settings.140 However, recent
ﬁndings that intranasal cocaine or intravenous opioids are
eﬀective reinforcers under PR schedules in humans141−143
suggest potential future translational utility in measuring the
therapeutic eﬃcacy of novel antiaddiction medications.
Consistent with the results of other D3R antagonists, 1
Table 2. Noncompartmental PK Parameters for 10 mg/kg (±)-1 in Mouse Plasma Following i.v. or p.o. Administration
Cmax
a Tmax
a AUClast
a (AUCinf)
a Ke t1/2
a F%
(ng/mL) (h) (h·ng/mL) (h·μg/mL) (h)
plasma (i.v.) 7369 0.08 7971 8895 0.55 1.241
plasma (p.o.) 522 2 1299 NCb NCb NCb 16.2%
aData are presented as mean; n = 3 mice per time point. bNC, not calculated.
Table 3. Brain Concentrations of (±)-1 in Mouse Following
i.v. or p.o. Dosing at 10 mg/kg
(±)-1
time (h) i.v. conc. ng/g (SD) p.o. conc. ng/g (SD)
0.5 28 928 (3716) 2979 (893)
2 17 798 (3292) 9231 (3478)
Table 4. Metabolic Stability Results for (±)-1 in Mouse Plasma and Liver Microsomes Compared to Positive Control
Compounds Procaine (Plasma), Testosterone (Phase I), and 4-Methyl Umbelliferone (Phase II)
(±)-1 positive control compounds
time plasma phase I phase II negative control procaine testosterone 4-methyl umbelliferone
0 100% 100% 100% 100% 100% 100% 100%
15 108% 97% 108%
30 103% 34% 64% 103%
60 90% 21% 55% 90% 9.70% 0% 3.10%
Figure 2. Eﬀects of i.p. vehicle or 1 (racemic and enantiomers) on PR
self-administration of METH. Data are presented as mean ± SEM; * p
< 0.05, ** p < 0.01, *** p < 0.001. Statistics in panel A refer to
number of METH injections (right axis) compared to vehicle; statistics
in panel B refer to break point values (last ratio completed),
normalized to baseline responding, compared to vehicle.
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eﬀectively reduced the number of METH injections and the
break points of treated rats. These ﬁndings suggest that 1
lowered the reinforcing eﬃcacy of METH, providing further
evidence that D3R signaling contributes to the rewarding value
of psychostimulant drugs.
3.2.3. Eﬀects of i.p. (±)-1 on Drug-Primed Reinstatement
Responding for METH in Rats. Figure 3A illustrates the
acquisition and extinction of METH self-administration.
Acquisition of self-administration began with a high dose (0.1
mg/kg/inj) of METH using an FR 1 schedule of reinforcement
over ﬁve daily training sessions, followed by seven daily training
sessions with a lower dose (0.05 mg/kg/inj) using an FR 2
schedule. This format allowed rapid acquisition of drug taking
with robust levels of lever pressing. Following seven daily
extinction-training sessions, in which lever presses resulted in
no drug delivery or cue presentation, the eﬀect of (±)-1 on
METH-primed reinstatement was tested (Figure 3B). One-way
ANOVA revealed that (±)-1 signiﬁcantly reduced METH-
primed reinstatement responding on the active lever [F2,31:
3.817, p = 0.033, Dunnett’s test: vehicle vs 3.0 mg/kg p > 0.05,
vehicle vs 10 mg/kg p < 0.05] but did not signiﬁcantly alter
inactive lever responding [F2,31: 2.12, p > 0.13, Dunnett’s test:
vehicle vs 3.0 mg/kg p > 0.05, vehicle vs 10 mg/kg p > 0.05].
Reinstatement of drug-seeking behavior, via stressors, drug-
associated cues or contexts, or acute exposure to the self-
administered drug or related drugs, is a widely used model of
drug craving and relapse (for review, see refs 144−146; see also
ref 147). As with previous D3R-selective antagonists and partial
agonists (e.g., 2,118 3,30 and 431), (±)-1 showed a dose-
dependent reduction in METH-primed reinstatement respond-
ing. These results add to the growing evidence that D3R
signaling plays an important role in the neurocircuitry that
drives relapse to drug taking and that D3R-selective
compounds could be useful therapeutics in the prevention of
relapse. However, it should be noted here that assessing a
medication that may prevent relapse requires that the subject
abstain from drug taking for a period of time. If the D3R
antagonists do not curb drug taking, then abstinence may be
very diﬃcult to achieve and hence clinical assessment for this
therapeutic beneﬁt will be challenging. It has been proposed
that a “Rosetta Stone approach” be taken to developing drugs
for addiction, wherein the addiction cycle is taken into account
for a pharmacological strategy.148 In the case of D3R
antagonists, additional treatment strategies may need to be in
place to help subjects attain abstinence before administering
D3R-selective therapeutics to prevent relapse.
3.2.4. Eﬀects of Acute Intravenous (±)-1 on Food−
Cocaine Choice in Cynomolgus Monkeys. In addition to the
rodent model studies, male cynomolgus monkeys were trained
to self-administer cocaine under a concurrent schedule in which
food was the alternative reinforcer. Under these experimental
conditions, complete cocaine self-administration dose−re-
sponse curves were determined each session (see ref 112 and
Supporting Information for methods). As shown in Figure 4, in
all but one monkey, (±)-1 either shifted the cocaine choice
curve to the left (4 subjects) or had no eﬀect (2 subjects). In
one monkey (C-6529), a decrease in choice of the highest
cocaine dose was observed. When group data were analyzed,
there was a main eﬀect of cocaine dose (F4,30 = 81.8, p <
0.0001) but no main eﬀect of drug pretreatment and no
interaction. Posthoc multiple comparisons indicated a signiﬁ-
cant increase in cocaine choice when 0.01 mg/kg cocaine was
available as the alternative to food. There were no signiﬁcant
eﬀects of the highest dose tested (5.6 mg/kg) (±)-1 on any of
the dependent variables of secondary interest (Table 5).
Although (±)-1 failed to reduce cocaine choice and increase
food choice, which would be a result more congruent with a
potential therapeutic, there are several testable hypotheses
generated from these results. Both concurrent food−drug
choice and PR responding are considered to be models of
reinforcing strength.149 However, the eﬀects of 1 are diﬀerent
in these two models, suggesting that they are measuring
diﬀerent aspects of self-administration (see ref 150 for an
example). One could hypothesize that drugs that share
discriminative stimulus eﬀects with cocaine would shift the
cocaine choice dose−response curve to the left, as seen with 1.
However, in preliminary ﬁndings from monkeys trained to
discriminate cocaine, 1 does not substitute for cocaine (M.A.
Nader and A.H. Newman, unpublished results). Several
investigators have shown that D2/D3R antagonists can shift
the cocaine choice dose−response curve to the left (e.g., refs
112, 151, and 152). It is also possible that the diﬀerences noted
are due to drug and/or species diﬀerences (see ref 153) or to
Figure 3. (A) Acquisition of METH self-administration and extinction
of self-administration. (B) Eﬀects of i.p. vehicle or (±)-1 on METH-
primed reinstatement of METH-seeking behavior. Data are presented
as mean ± SEM; * p < 0.05 compared to vehicle.
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diﬀerences in drug histories between the rat PR study and the
monkey food−cocaine choice study. On the basis of our
experience and the literature, D3R antagonists are most
eﬀective in models of relapse, and perhaps this is the clinical
end point that should be singly targeted with this class of drugs.
Nevertheless, from a basic research standpoint, additional
behavioral models of addiction must be explored to fully
elucidate the role of D3R in the development of addiction.
Further, as described previously, neurobiological changes that
occur upon chronic exposure to psychostimulant drugs and also
during abstinence must also be quantiﬁed to better ascertain
optimal timing of administration of D3R antagonists or partial
agonists for potential therapeutic beneﬁt. One obvious
limitation to the present study is that 5.6 mg/kg was the
highest dose that could be solubilized and administered
intravenously to these subjects. It is certainly possible that
the level of D3R occupancy required to observe behavioral
eﬀects was not achieved or sustained and future D3R
occupancy determination, potentially using PET imaging or
another biomarker, will need to be assessed.
3.2.5. Eﬀects of Acute or Repeated Intravenous (±)-1 on
Food−METH Choice in Rhesus Monkeys. In order to more
fully model the clinical situation in which chronic drug
treatments are likely to be employed, a follow-up study was
Figure 4. Eﬀects of i.v. vehicle or (±)-1 on cocaine choice in seven monkeys individually and as a group (lower right panel). Ordinates, percent of
total reinforcers earned that resulted in cocaine injections. Abscissae, dose of cocaine (mg/kg) available as an alternative to a food pellet. Data in
lower right panel represent mean ± SEM.
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conducted in rhesus monkeys that self-administered METH in
which (±)-1 was administered for 5 consecutive days. In two of
three monkeys, 5 day treatment with 3.0 mg/kg (±)-1 (i.v.)
produced a leftward shift of the METH choice curve (Figure
5). Eﬀects of acute treatment had a more pronounced eﬀect in
one monkey (R-1690), suggesting tolerance developed in this
subject. When grouped data were analyzed, there were no
statistically signiﬁcant eﬀects of 3.0 mg/kg (±)-1 on any of the
dependent variables of secondary interest (Table 5). In addition
to the possibility of suboptimal D3R occupancy, pharmacoki-
netic studies were conducted only in mice. Clearly, the
pharmacokinetics and metabolism of 1 in monkeys may diﬀer.
These experimental sessions are approximately 2 h in duration,
and drug self-administration doses are presented in ascending
order. If the half-life of 1 is short in monkeys, then it is possible
that there is insuﬃcient drug blocking D3Rs later in the session
when higher cocaine doses are available.
An additional possibility is that the elevated DA from cocaine
or METH is displacing 1 and that D3R antagonists are less
eﬀective in models of self-administration compared to
reinstatement models or under conditions in which treatment
occurs in the absence of psychostimulant availability. Indeed, a
PET imaging study in rhesus monkeys with [18F]LS-3-134
suggested a high level of competition between this D3R-
selective PET imaging agent and endogenous dopamine in the
absence of a psychostimulant drugs.154 Thus, in the presence of
psychostimulants, competing DA levels may render D3R
antagonists ineﬀective. Future research is clearly needed to
better understand the conditions under which D3R-selective
compounds are eﬀective in nonhuman primate models of
psychostimulant addiction and which of these models is reliably
translatable to human psychostimulant abusers.
4. DISCUSSION
In radioligand competition binding experiments using [3H]N-
methylspiperone and membranes from HEK293 cells express-
ing hD2R, hD3R, or hD4R, (±)-1 exhibits nearly 400- and
1300-fold D3R selectivity over D2R and D4R, respectively.
This is more pronounced when considering the enantiose-
lectivity of D3R for the R-enantiomer.5 The in vitro D3R
selectivity of 1, particularly (R)-1, was an improvement over
previous generations of 2,3-dichlorophenylpiperazinebutylar-
ylcarboxamides (e.g., 3).25,75 As such, 1 and its enantiomers
were some of the most D3R-selective ligands in our library and
thus the tools we chose to test in vivo.
To evaluate the in vivo stability of 1, plasma pharmacoki-
netics (PK) was studied in mice, revealing plasma stability 0−
1.5 h following i.v. administration of 1. Additionally, 1 was
orally bioavailable with good brain penetration. Compound 1
was actively metabolized by liver microsomes, but it showed a
terminal half-life of approximately 1−1.5 h following i.v.
administration. It should be noted that metabolism and PK
studies were done in mice and thus these parameters may be
diﬀerent across species. Clearly, PK studies need to be extended
to nonhuman primates and brain imaging needs to be utilized
to study pharmacodynamics of these compounds entering the
brain and occupying D3R. Nevertheless, these pharmacokinetic
parameters appeared to be promising for a translational
candidate, justifying further exploration in both rat and
nonhuman primate models of drug addiction.
Figure 5. Eﬀects of acute and chronic administration of (±)-1 (i.v.) on
METH choice in three rhesus monkeys (mean ± SEM of days 3−5 of
daily treatment). Ordinates, percent of total reinforcers earned that
resulted in METH injections. Abscissae, dose of METH (mg/kg)
available as an alternative to a food pellet.
Table 5. Secondary Dependent Variables in Food−Drug
Choice Studies after Administration of Vehicle or (±)1
cynomolgus monkeys
vehicle 5.6 mg/kg (±)-1
food reinforcers 30.0 ± 1.9 25.5 ± 2.4
cocaine injections 13.4 ± 1.3 15.5 ± 2.2
total reinforcers 43.4 ± 2.0 40.3 ± 1.7
intake (mg/kg) 0.77 ± 0.11 0.63 ± 0.11
choice ED50 0.023 ± 0.006 0.012 ± 0.002
rhesus monkeys
baseline 3.0 mg/kg (±)-1
food reinforcers 19.9 ± 2.3 14.4 ± 2.8
METH injections 14.8 ± 2.8 15.2 ± 1.9
total reinforcers 34.7 ± 0.8 29.7 ± 4.5
intake (mg/kg) 1.08 ± 0.11 1.08 ± 0.23
choice ED50 0.024 ± 0.011 0.011 ± 0.003
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Previous studies have demonstrated a trend in which D3R
antagonists and partial agonists typically do not aﬀect
psychostimulant self-administration with low FR response
requirements but attenuate drug taking in paradigms that
increase the response requirement (e.g., high FR or PR models)
or second-order schedules,29−31,126,155−157 suggesting that D3R
antagonism does not aﬀect the primary reinforcing eﬀects of
drugs but reduces the motivation to self-administer drugs.48,158
Consistent with that view is the success of D3R antagonists in
rodent models of relapse, such as drug-, cue- and stress-induced
reinstatement.28−31,157,159 Compound 1 signiﬁcantly reduced
PR responding for METH, as measured by break point. There
was no clear diﬀerence in potency seen between the (R)- and
(S)-enantiomers; however, this study did not test a suﬃcient
range of doses to reliably determine whether one enantiomer
was more potent than the other in reducing PR break point in
rats. Racemic 1 signiﬁcantly attenuated METH-primed
reinstatement as well. Overall, (±)-1 (3.0−10 mg/kg, i.p.)
was eﬃcacious in two rat models of drug self-administration
and drug seeking (i.e., reinstatement).
In the food−cocaine choice model, cynomolgus monkeys
were allowed to choose either a food reward or an i.v. cocaine
infusion, with the cocaine dose varied across trials. Overall, 1
had inconsistent eﬀects; when all data were combined, the
general eﬀect that emerged was that 1 shifted the dose−
response curve of cocaine to the left, i.e., it potentiated cocaine
choice over food. In the food−METH choice model using
rhesus monkeys, the result was similar: 1 tended to shift the
METH dose−response to the left or have no eﬀect. One
subject (R-1691) appeared to develop tolerance to the eﬀect of
1. The results of these studies may not appear to support
further investigation. However, it must be noted that the food−
drug choice model is not directed toward relapse, which the
rodent studies with 1 and other D3R antagonists most support.
Further evaluation of 1 and newer generation D3R antagonists
and partial agonists are underway in nonhuman primate
reinstatement to drug seeking models to determine if the
rodent studies can be replicated with these agents in primates
with a history of chronic drug taking. Chronic dosing with the
treatment agent can also be evaluated in the nonhuman
primates, which will also inform human studies.
In contrast to D3R antagonists such as (±)-1 and 7, D3R
partial agonists pose several interesting questions. For example,
it is known that chronic administration of receptor agonists
commonly results in receptor downregulation, whereas chronic
administration of receptor antagonists commonly results in
receptor upregulation. With regard to partial agonists, a recent
PET imaging study in cynomolgus monkeys found that chronic
aripiprazole, a D2R partial agonist, produced diﬀerent eﬀects on
D2R binding potential: it appeared to increase binding when
the subject had, on average, low D2R availability and decreased
binding potential in monkeys with higher average D2R
availability.160 Thus, depending on the long-term consequences
of cocaine or METH abuse on receptor availability, the eﬀects
of receptor partial agonists may be diﬀerent than antagonists.
There are behavioral nuances as well. Recently, it was reported
that the eﬀects of aripiprazole on cocaine−food choice varied
depending on whether monkeys were given access to cocaine
during aripiprazole treatment.112 Thus, it remains possible that
in nonhuman primates and humans D3R partial agonists would
be more eﬀective in a setting in which cocaine or METH were
not available (e.g., residential treatment facility), at least in the
early stages of treatment. Finally, there are ongoing studies to
evaluate the eﬀects of antagonists and partial agonists on
peripheral D3Rs, particularly in regard to potential synergistic
eﬀects in combination with cocaine- and METH-induced
elevations in heart rate and blood pressure, a key treatment risk
that must be thoroughly evaluated and thoughtfully considered
when describing potential treatment compounds.
5. OVERALL CONCLUSIONS AND OUR PERSPECTIVE
The D3R remains an enigmatic target for addiction
pharmacotherapy. The translation between rodent and nonhu-
man primate addiction models and again between nonhuman
primate addiction models and humans in a clinical setting is
fraught with pitfalls. Predecessors of 1 and 7 have failed to
successfully clear the hurdles that lead to successful clinical
trials. The partial agonist 8 was eﬃcacious in rodent and
primate models of addiction, but it failed in clinical trials for
cocaine abuse.118,161,162 Compound 4 looked promising in
rodent models of drug taking and drug seeking, but poor
bioavailability and short half-life in primates led GlaxoSmithK-
line to halt further development of the compound.118 The
recent failure of buspirone, as described above, may also bode
poorly for continuing to pursue this target.
Compound 1 will likely remain a research tool for basic and
preclinical studies. Its inconsistent behavioral proﬁle in
nonhuman primates thus far may be directly related to a
poor pharmacokinetic proﬁle, lack of target engagement at the
doses and time points tested, or simply lack of eﬃcacy in these
models. Future studies to parse out the contributing factors to
its demise, before reaching the clinic, will be used for the next
generation of drug design and choice of behavioral models.
Nevertheless, newer generation agents in our laboratory and
others are already making their way forward in development
and will soon be evaluated in these and other models of drug
abuse and neuropsychiatric disorders. Only continued drug
design using structure−activity relationships and in vivo data
will ultimately lead us to successfully identify D3R-selective
compounds that have appropriate drug-like properties. So far,
this goal remains to be achieved.
A key concern in the ﬁeld of addiction medicine and indeed
all neuropsychiatric drug discovery is the eﬀectiveness of animal
models to evaluate preclinical candidates.163,164 In one of the
ﬁrst studies using D3R partial agonists, it was reported that the
eﬀects of 8 were diﬀerent in models of drug seeking compared
to drug self-administration.70 The study of D3R compounds
has provided a better understanding of the importance of
models that incorporate long-term cocaine and METH self-
administration and a clearer perception of the importance of
behavioral phenotype. For example, it appears that the
behavioral pharmacology of D3R partial agonists are diﬀerent
depending on whether the subjects are drug-naiv̈e or have a
drug history123 and, for D3R agonists, whether the drug is
cocaine or METH.124 Moreover, individual diﬀerences in the
eﬃcacy of D3R antagonists to reduce drug self-administration
have been found involving acute vs chronic treatment,165 drug
history,165 and social rank.107 These ﬁndings are reﬂected in
human imaging studies involving the D3R-preferential PET
ligand [11C]PHNO166 in cocaine and METH abusers.42−44,167
There are important temporal diﬀerences in psychostimu-
lant-induced D3R dysregulation that should be taken into
account for the D3R’s therapeutic potential. For instance,
studies designed to examine the time course of changes in D3R
binding and sensitivity observe D3R upregulation after
prolonged abstinence (30−45 days after the last cocaine
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/jm501512b
J. Med. Chem. 2015, 58, 5361−5380
5373
administration) but not during self-administration or within 7
days of abstinence.133,168,169 Furthermore, the subjects in some
of the recent human imaging studies demonstrating D3R
upregulation following chronic cocaine or METH use were
scanned on average 18.5 ± 20.542 and 50.1 ± 64.443 days,
respectively, after their most recent drug use, which appear to
reﬂect substantial periods of abstinence. Therefore, although it
is clear that D3R expression is signiﬁcantly altered in drug
abusers, perhaps there is a speciﬁc window of time in the
addiction cycle in which the therapeutic potential of D3R
antagonists and partial agonists could be maximally beneﬁcial.
The diﬃculties of treating drug addiction are compounded
by the high incidence of comorbid neuropsychiatric disorders
with substance use disorders, including depression, anxiety,
ADHD, and schizophrenia.170−173 Further complicating the
search for translational medications for addiction is the
complexity of D3R receptor signaling and genetics. There is
not yet a clear understanding of the role of D1R−D3R
heteromers in the striatum or whether receptor heteromers are
a viable target for drug development. We have recently
speculated on the possible role of the D1R−D3R heteromer
in drug memory reconsolidation, and future studies in this area
are of great interest.174 Additionally, there are a number of
studies linking various D3R gene polymorphisms with
neuropsychiatric disorders. In particular, rs6280, which encodes
the functional missense mutation Ser9Gly, may enhance
reward-related DA release.175 This particular polymorphism
has been associated with nicotine dependence,176 alcohol
dependence,177 and early onset heroin dependence.178 Further
study will be necessary to determine the signiﬁcance of receptor
heteromerization and genetic variation at D3R in the
development of substance use disorders or in the response to
an antiaddiction pharmacotherapeutic.
Given these considerations, it is important that the preclinical
and clinical studies showing negative results with D3R
antagonists and partial agonists thus far not be used to
prematurely rule out the utilization of these pharmacotherapies
for addiction. Instead, these studies should be used to guide
future eﬀorts in designing more appropriate behavioral models
to evaluate D3R compounds and determining the subsets of
individuals in which D3R pharmacotherapies can be most
eﬀective. To reiterate, assessing a medication that may have its
greatest utility in the prevention of relapse, as may be the case
for D3R pharmacotherapy, requires that clinical subjects abstain
from drug taking for a period of time. On the basis of
preclinical results thus far, D3R antagonists do not eﬀectively
reduce active drug taking, but they do reduce relapse-like
behavior. Therefore, if D3R antagonists are best suited for a
role as a relapse-prevention treatment, then they will likely only
be successful in the framework of a larger treatment program in
which subjects have already attained abstinence. Trials designed
to test D3R antagonists in patients actively using drugs may not
see any attenuation in drug taking and would not be well-suited
to evaluate the abstinence-maintaining therapeutic potential of
this compound class. Hence, lessons learned from the
buspirone case described in Section 2.3 should be used in
future psychostimulant medication development.
This Perspective highlights the importance of developing
selective compounds to better understand the role of D3R in
addiction. It is our opinion that repurposing drugs that are
clinically available has utility in guiding future research.
However, the use of drugs with D3R aﬃnity, but also many
other targets (e.g., buspirone), should not be used to exemplify
the pharmacology, biology, and physiology related to this
important target. Recently, a new D3R-preferential partial
agonist, 23 (BP1.4979 in Chart 3, communicated by Jean-
Charles Schwartz, Dopamine 2013 meeting), was introduced by
Bioprojet, and a clinical trial on smoking cessation has begun
(ClinicalTrials.gov identiﬁer NCT01785147). Although data
remain unpublished, presumably this compound has been
vetted through all of the in vitro and in vivo assays that Pharma
has at its disposal (as compared to academic drug discovery
programs such as ours) to be considered for translation to
human studies. The fact that 23 is a partial agonist is of further
interest and will provide answers to some of the questions
regarding D3R eﬃcacy posed above. Results of these clinical
investigations will be of great interest to our community of
addiction researchers and will very likely determine if the D3R
remains a target to pursue for smoking cessation as well as
other substance use disorders. One ﬁnal thought is that D3R
antagonists and partial agonists may not prove to be eﬃcacious
or safe for treatment of cocaine or METH addiction but may
still hold promise for addictions to other substances, such as
nicotine, opiates (including prescription pain killers, e.g.,
oxycodone), alcohol, food and Δ9-tetrahydrocannabinol
(THC), the active ingredient in marijuana. Hence, it is our
perspective that the development of selective D3R ligands, with
varying eﬃcacies, as research tools that are active and
metabolically stable in vivo, can help to elucidate underpinnings
of addiction and other neuropsychiatric disorders. Hence,
future research and development of these agents toward these
therapeutic end points remains vitally important. Further,
developing animal models that can translate preclinical research
is challenging and yet key to ﬁnding pharmacotherapeutic
treatments for this underserved patient population.
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